Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of Cisplatin-induced hearing loss in patients with localized, non-metastatic, solid tumors.
The pharmaceutical company added that the findings from two open-label, randomized Phase 3 trials, SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431 demonstrated around 50 percent reduction in the occurrence of cisplatin-induced hearing loss in patients treated with cisplatin and sodium thiosulfate.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.